AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00551161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memantine
Description: 24-week observational lead-in period, wherein patients already on a stable dose of donepezil, rivastigmine, or galantamine continue on that dose, followed by a 24-week open-label memantine period, wherein patients receive open-label memantine treatment titrated to a dose of 10 mg orally b.i.d., in addition to their ongoing stable cholinesterase inhibitor treatment
Study NCT02745691 — intervention group
Intervention type: OTHER
Intervention: Surgery
Description: Thoracic surgery for lung cancer
Study NCT02745691 — intervention group
Intervention type: OTHER
Intervention: Radiochemotherapy
Description: Either chemotherapy or radiotherapy alone or combination of both (either subsequent or concurrent)
Study NCT02745691 — intervention group
Intervention type: OTHER
Intervention: Targeted therapy
Description: New targeted therapies for lung cancer
Study NCT02745691 — intervention group
Intervention type: OTHER
Intervention: Immunotherapy
Description: New immunotherapies for lung cancer
Study NCT02258334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent vaccine, 2014-2015 formulation
Description: 0.5 mL, Intramuscular
Study NCT02258334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone I®ntradermal vaccine, 2014-2015 formulation
Description: 0.1 mL, Intradermal
Study NCT02258334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High Dose vaccine, 2014-2015 formulation
Description: 0.5 mL, Intramuscular
Study NCT02908074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGS649
Description: Capsules will be taken weekly for a maximum of 24 weeks
Study NCT01314105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Description: BIBF1120 twice daily along with standard therapy of PLD + carboplatin
Study NCT01314105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Description: BIBF1120 twice daily along with standard therapy of PLD + carboplatin
Study NCT03437928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Directional Deep Brain Stimulation
Description: Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation
Study NCT01872780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: single oral administration of 4mg of rosiglitazone
Study NCT01872780 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: CYP2C8 genotype
Description: CYP2C8\*11.
Study NCT01734850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Intravenous busulfan
Study NCT01734850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cal-1 modified HSPC
Description: Hematopoietic progenitor/stem cells (HSPC) modified with LVsh5/C46 (Cal-1)
Study NCT01734850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cal-1 modified CD4+ T lymphocytes
Description: CD4+ T lymphocytes modified with LVsh5/C46 (Cal-1)
Study NCT02374190 — intervention group
Intervention type: OTHER
Intervention: Standard Hospital Care
Description: We described patient characteristics using percentages for categorical data, means and SD or medians and IQRs for normally and non-normally distributed continuous variables, respectively. Statistical comparisons for differences in baseline characteristics among patients admitted during regular hours and off-hours were performed using χ2 tests for categorical variables, t-tests and Wilcoxon rank sum tests for normally and non-normally distributed continuous variables, respectively. DTB times were described using median and IQR based on time of admission. All p values were calculated as two-tailed analyses, using a significance level of 5%.
Study NCT05595330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lymphedema prevention protocols
Description: Coming for surgery: A PPT lecture; 2. A seminar; 3. Patients were given a lymphedema prevention brochure; 4. Diary cards for exercise is given and instruct patients to fill out daily; 5. Establish a WeChat group.~The first chemotherapy:1. Review diary card and provide guidance and education. 2. A PPT lecture; 3. A seminar; 4. Play functional exercise videos in the recovery room; 5. Rehabilitation volunteers come to the ward to form mutual help groups with patients under the guidance of subject team members; 6. Instruct regular exercise and avoid behaviors that can lead to lymphedema. 7. Ask about the exercise and whether there is any swelling and discomfort and give guidance.~The second chemotherapy: 1. A PPT lecture; 2. A seminar; 3. Play functional exercise videos in the recovery room.~The third chemotherapy: 1. Routine nursing; 2. Assess patients' knowledge of lymphedema prevention and exercise compliances; 3. Play functional exercise videos in the recovery room.
Study NCT03885856 — intervention group
Intervention type: OTHER
Intervention: single row repair technique
Description: single row repair technique
Study NCT03885856 — intervention group
Intervention type: OTHER
Intervention: double row repair technique
Description: double row repair technique
Study NCT03728114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIC
Description: Adults allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
Study NCT03728114 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham RIC
Description: Adults allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
Study NCT02743793 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Study NCT03543722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: National Career Coach Program
Description: Intensive employment services as described above.
Study NCT03543722 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Local Community Resources Program
Description: Usual employment services as described above.
Study NCT04503382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kindness Media
Description: As described above, the intervention is a series of short videos that display acts of kindness or ideas about kindness. These videos are edited together into one reel that was 8 minutes long.
Study NCT04503382 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kindness Media
Description: As described above, the intervention is a series of short videos that display acts of kindness or ideas about kindness. These videos are edited together into one reel that was 8 minutes long.
Study NCT04517370 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional/Pixel CO2 laser
Description: The treatment is done with a specialized vaginal applicator which allows treatment of vagina, using the Femilift fractional micro ablative CO2 laser system (Alma Lasers, Israel), according to the usual protocol (Laser mode: Pulse, Energy: 40-80 mj/pulse).~Before treatment, 5ml of topical anesthetic ointment (10% lidocaine in Vaseline base) will be spread in the vagina and on the vestibule for 30 minutes in both groups to avoid pain from the laser, as well as to allow the comparison between the groups (patients in both groups will not experience pain and therefore will remain blinded to their allocation).
Study NCT04517370 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Fractional/Pixel CO2 laser
Description: The treatment is done with a specialized vaginal applicator which allows treatment of vagina, using the Femilift fractional micro ablative CO2 laser system (Alma Lasers, Israel), according to the usual protocol (Laser mode: Pulse, Energy: 40-80 mj/pulse).~Before treatment, 5ml of topical anesthetic ointment (10% lidocaine in Vaseline base) will be spread in the vagina and on the vestibule for 30 minutes in both groups to avoid pain from the laser, as well as to allow the comparison between the groups (patients in both groups will not experience pain and therefore will remain blinded to their allocation).
Study NCT04048252 — intervention group
Intervention type: OTHER
Intervention: Focus group creation
Description: Patients will join with researchers for a 2 hour recorded group discussion to highlight themes identified to require educational intervention
Study NCT04048252 — intervention group
Intervention type: OTHER
Intervention: Workshop
Description: Patients will attend 3-4 workshops on eg disease knowledge, medication management and side effects, adapted physical activity and nutrition
Study NCT04263090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rigosertib
Description: Rigosertib will be dosed twice a day for 21 consecutive days, followed by 7 days off treatment (each cycle duration: 28 days). Rigosertib escalation will occur with three dose levels (dose D1: 280mg twice daily; dose D2: 560mg qAM, 280mg qPM; dose D3: 560mg twice daily).
Study NCT04263090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be dosed once ever 2 weeks (twice per 28-day cycle; standard fixed dose of 240mg).
Study NCT03876938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant
Description: aprepitant 125 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy aprepitant 80 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
Study NCT03876938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine 10 mg
Description: olanzapine 10 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy olanzapine 10 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
Study NCT03876938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine 5 mg
Description: olanzapine 5 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy olanzapine 5 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
Study NCT00259324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Activity
Description: Diet and Activity
Study NCT00259324 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diet and Activity
Description: Diet and Activity
Study NCT00284089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab was administered by intravitreal injection in the study eye. Intravitreal injection was performed by the investigator following slitlamp examination.
Study NCT02935582 — intervention group
Intervention type: DRUG
Intervention: Enstilar® aerosol foam
Description: Treatment according to local labelling
Study NCT02935582 — intervention group
Intervention type: DRUG
Intervention: Other topical
Description: Treatment according to local practise
Study NCT01925157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3090106 - SQ
Description: Administered SQ.
Study NCT01925157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3090106 - IV
Description: Administered IV.
Study NCT01925157 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SQ
Description: Administered SQ.
Study NCT02858180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)
Description: 1 pill once daily of SOF/LDV FDC
Study NCT01139099 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group Psychotherapy
Description: integrated group psychotherapy, including the interpersonal and cognitive group therapy
Study NCT02061449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Study NCT02061449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Study NCT02061449 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Focal lesional radiation
Study NCT03251794 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: three dimensional ultrasound
Description: evaluation of the suprarenal glands
Study NCT03251794 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: color Doppler
Description: Doppler evaluation of the suprarenal artery
Study NCT03066219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BRM421
Description: A topical solution of BRIM421 ophthalmic drops
Study NCT03066219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle ophthalmic drops
Study NCT03767556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Powerbreathe® K5
Study NCT00894790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: celecoxib 200 mg BID (twice a day) with a loading dose of 400 mg
Study NCT00894790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral Diclofenac
Description: diclofenac 75 mg tablet BID (twice a day)
Study NCT02849392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pistachio added 20% of kcals to diet
Description: Pistachio added 20% of kcals to diet
Study NCT02101359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2380
Description: 200 microlitres of T2380 will be administrated intracamerally
Study NCT02101359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mydriatics
Description: 3 drops of tropicamide and phenylephrine were instilled 30 minutes before surgery. The second and the third instillation of both phenylephrine and tropicamide will be realised respectively within 20 and 10 minutes before surgery.
Study NCT02101359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracaine
Description: Two drops of tetracaine were instilled in the eye to be operated 5 minutes and 1 minute before surgery
Study NCT02101359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine
Description: Two drops of tetracaine were instilled in the eye to be operated 5 minutes and 1 minute before surgery
Study NCT04660708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: manual physical therapy
Description: Previously described in the arm description
Study NCT01876979 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IMF Screws
Description: stainless steel screws placed in bone
Study NCT01876979 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erich Arch Bars
Description: Surgical braces wired around teeth
Study NCT01627301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device-Guided Breathing (DGB)
Description: The RESPeRATE device will be used for 15 minutes of device-guided breathing daily for 8 weeks. The participant places the elastic belt with a respiration sensor around the upper abdomen, and wears earbuds for audio feedback. The device monitors the breathing rate, calculates inspiration and expiration times, and generates a personalized melody of two distinct ascending and descending tones for inhalation versus exhalation. Users effortlessly entrain their breathing pattern with the tones, and the device gradually guides the user to a prolonged expiration time and slower respiratory rate (to \< 10 breaths/minute). The device automatically stores usage data, allowing for quantification of adherence and performance.
Study NCT01627301 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham DGB
Description: The sham device is identical to the DGB device, except it does not guide respiratory rates to slow down and instead maintains a rate of 14 breaths per minute. The sham device is used for 15 minutes per day for 8 weeks.
Study NCT01627301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagal Nerve Stimulation (tVNS)
Description: tVNS is a noninvasive method that involves placing a device over the skin overlying the vagus nerve on the neck. The device delivers mild electrical stimulation, using transcutaneous electrical nerve stimulation (TENS) unit. The stimulation is increased until there is a vibration and slight muscle contraction in the lower face or neck. Then the stimulation is delivered for 2 minutes on the left side of the neck, and on the right side of the neck, for a total of 4 minutes. The tVNS device is used twice daily for 8 weeks.
Study NCT01627301 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tVNS
Description: Sham stimulation is delivered using a device that is identical to the gammaCore device but is programed to deliver a lower frequency that can be felt by the participant but does not actually stimulate the vagus nerve. The sham device is used twice daily for 8 weeks.
Study NCT01841567 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mepilex border post. op
Study NCT01841567 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mepilex border post op
Study NCT04527913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdental Oral Hygiene Instruction (Int-OHI)
Description: Int-OHI will be given focusing on the interdental device of the allocated group for each patient and will be given only once at timepoint T-7. No further formal Int-OH instructions will be given, unless specifically asked by the patient.~Int-OHI will be delivered by trained dental hygienist/periodontist.
Study NCT04527913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One session of professional supragingival scaling and polishing
Description: A session of professional supragingival scaling and polishing: instrumentation will be performed by a trained dental hygienist/periodontist with great care in performing exclusively coronal maneuver. No instrumentation or exploring of the gingival crevice/ sulcus will be performed.
Study NCT04527913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Hygiene Instruction (OHI)
Description: OHI will be given focusing on manual toothbrushing and will be given only once at timepoint T-7. No further formal OH instructions will be given, unless specifically asked by the patient.~OHI will be delivered by trained dental hygienist/periodontist.
Study NCT01451697 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control (Placebo)
Description: The control condition will involve relaxation training.
Study NCT01388478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-pramipexole
Description: R-pramipexole will be taken as a liquid and start at one teaspoon (5 ml) twice a day for a total dose of 100 mg/day. After 4 weeks, the dose will double (two teaspoons twice a day, or a total of 200mg/day). Four weeks later the dose will be increased again to 2 1/2 teaspoons twice a day (total of 300mg/day) where it will remain for the remaining 16 weeks of study treatment. Prior to each increase, participants and their study partners will be interviewed regarding any possible side effects or problems. These findings will be discussed with the physician prior to increasing the study drug dose. The dose will only increase if the participant is not having side effects.
Study NCT04668534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS 10
Description: Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)
Study NCT04668534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS 25
Description: Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)
Study NCT04668534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)
Study NCT01359878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate
Description: 2 gram intra venous
Study NCT01359878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline
Description: Isotonic saline in equivalent volume - 100 ml
Study NCT00683397 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Screening of thrombophilia
Study NCT01589107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video decision aid
Description: video decision aid
Study NCT00316862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00316862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00316862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo Surgery
Study NCT00316862 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation